Global Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κB) Inhibitors Market – Industry Trends and Forecast to 2030

Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κB) Inhibitors Market Analysis and Size

The increasing cancer population and rise in novel treatment-seeking rate can act as a positive indication for the growth of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) inhibitors market. In addition to this, strong research and development activities can also increase the market position. Presently, numerous companies are working in this area, creating a strong pipeline of about more than 12 active products.  

Data Bridge Market Research analyses a growth rate in the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) inhibitors market in the forecast period 2023-2030. The expected CAGR of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) inhibitors market is tend to be around 11% in the mentioned forecast period. The market is valued at USD 2.60 billion in 2022, and it would grow upto USD 6 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κB) Inhibitors Market Scope and Segmentation

​​​​​​​

Market Definition

NF-κB (Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells) is a transcriptase factor which involves a number of physiological activities cellular process that includes cell proliferation, apoptosis and inflammatory response. Numerous diseases such as tumor, inflammatory joints disorders and asthma involves a NF-κB pathways. NF-κB is the matter of active research among many pharmaceutical companies as a target for anti-cancer therapy.

Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κB) Inhibitors Market Dynamics

Drivers

• Increasing Prevalence of Cancer

Cancer is a top cause of death globally, accounting for approximately 10 million deaths in 2020. The most common in 2020 were breast cancer which was around 2.26 million cases. Breast cancer is the most common type, with 290,560 new cases expected in the U.S. in 2022. The next most prevalent cancers are prostate cancer and lung cancer. There was an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020 globally. Thus, this factor which increases the demand for nuclear factor kappa-light-chain-enhancer of activated b cells (NF-κB) further boosts market growth.

Opportunities

• Rising Clinical Development Associated with the Products

Several major players are indulging themselves in launching multiple products that will help in the growth of the market. For instance, Reata’s Bardoxolone Methyl is under development by Reata Pharmaceuticals in late clinical-stage and has received Sakigake priority review designation Japan for treating diabetic kidney disease (DKD). AnGes’s AMG0101 has completed the phase III trials (ointment) in Japan for Atopic Dermatitis. The same drug is under phase I trial for Low Back Pain due to Disc Degeneration in United States. MedDay Pharmaceuticals’ MD-1003 is under Phase III stage of development as the most favourable emerging therapy for the future. Catabasis’s Edasalonexent is being assessed for phase II clinical studies by Catabasis Pharmaceuticals. The potential candidate has been awarded orphan drug, fast track and rare pediatric disease designations for treating Duchenne muscular dystrophy (DMD). Thus, all these developments will lead to the growth of the market.

• Increasing Healthcare Expenditure And Government Support

With the rising prevalence of cancer, the growing awareness for the disease and the associated treatment is also expanding. Various government initiatives tend to provide better and more convenient treatments combined with favourable reimbursement policies that are expected to increase the industry growth. Furthermore, increasing acceptance of advanced therapies is projected to drive the market.

Restraints/Challenges

• High Cost of Treatment

The rising expenditure associated with the medications impede the market growth. Several genetic drugs cost high, and people in highly developing and underdeveloped countries cause the under treatment of numerous patients. This hinders the market growth.

This nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) inhibitors market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) inhibitors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κB) Inhibitors Market Scope

The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) inhibitors market is segmented on the basis of drugs, indication, route of administration, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drugs

• Denosumab
• Bortezomib

Indication

• Multiple Myeloma
• Giant Cell Tumor of Bone
• Hypercalcemia
• Others

Route of Administration

• Intravenous
• Subcutaneous
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κB) Inhibitors Market Regional Analysis/Insights

The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) inhibitors market is analyzed and market size insights and trends are provided by drugs, indication, route of administration, end-users and distribution channel as referenced above.

The major countries covered in the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) inhibitors market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for nuclear factor kappa-light-chain-enhancer of activated b cells (NF-κB) inhibitors market throughout the forecasted period because of the high incidence rate of cancer, increasing awareness and development activities for nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) inhibitors  therapeutics.

Asia-Pacific dominates the market because of the healthy improvement in healthcare infrastructure and huge economic development. Furthermore, the healthy improvement in healthcare infrastructure and economic boost the market growth.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κB) Inhibitors Market Share Analysis

The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) inhibitors market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to nuclear factor kappa-light-chain-enhancer of activated b cells (NF-κB) inhibitors market.

Key players operating in the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) inhibitors market include:

• Sanofi (France)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• AbbVie Inc. (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Fresenius Kabi AG (Germany)
• Dr. Reddy’s Laboratories Ltd (India)
• Merck & Co., Inc. (U.S.)
• Apotex Inc (Canada)
• Amgen inc. (U.S.)
• AnGes, Inc.(Japan)

SKU-52843